新冠疫苗知识产权豁免

新冠疫苗知识产权豁免 waiver of COVID-19 vaccine¹ patents

 

6月12日至17日在瑞士日内瓦举行的世界贸易组织第12届部长级会议就新冠疫苗知识产权豁免达成部长决定。商务部称，在会议谈判的关键阶段，作为新冠疫苗生产和供应大国，中国主动宣布不寻求享受豁免决定所提供的灵活性，彰显了大国担当。

 

A major decision on the waiver of intellectual property rights for COVID-19 vaccines² was made at the World Trade Organization's Ministerial Conference Twelfth Session (MC12) from June 12 to 17 in Geneva, Switzerland. At a pivotal stage of MC12 negotiations³, China, as a major producer and a supplier of COVID-19 vaccines, announced that it will forego the flexibility⁴ of the Trade-Related Aspects of Intellectual Property Rights waiver on COVID-19 vaccines, which shows China's sense of responsibility as a major country, an official with the Ministry⁵ of Commerce said.

分享到：